OS Therapies opened higher at $0.88, compared with its previous close of $0.87. In the last trading session, the stock traded between $0.72 and $0.88. It showed a downward intraday trend.
An investment of $100 made 3 years ago in OS Therapies is now worth
$ 29.88
Resulting in a loss of
$ 70.12 (70.12%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.12 (-14.01%)
Day High
$0.88
Day Low
$0.72
Day Open
$0.88
Prev Close
$0.87
Volume
12,87,390
1W Return
-35.23%
1M Return
-52.08%
3M Return
-53.27%
6M Return
-56.14%
1Y Return
-60.32%
Market Cap ($ Mn)
39
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-1,719.63%
EPS (TTM)
-
1 Week
-35.23%
1 Month
-52.08%
3 Months
-53.27%
6 Months
-56.14%
9 Months
-37.50%
OS Therapies initiates UK MHRA CMAA process for Herlystic
OS Therapies initiated CMAA process with UK MHRA for Herlystic. Application covers prevention or delay of recurrence in pulmonary metastatic osteosarcoma. Company expects to complete CMAA process later in Q4 2026. Potential early market access decision expected from MHRA in Q1 2027.
2 days agoOS Therapies secures $7.2M gross proceeds from warrant inducement closing
Initial closing raised $7.2 million in gross proceeds from seven investors exercising warrants at $1.30 per share. Company issued 5,517,253 new warrants at $1.40 per share to participating holders. Funds will support BLA and CMAA submissions for Herlystic planned for Q4 2026. Combined with $7 million in accrued U.K. R&D tax credits, runway extends through key milestones.
24 days agoOS Therapies reports 72.7% three-year survival rate in osteosarcoma trial
Final three-year overall survival rate reached 72.7% for OST-HER2 patients. Historical control group showed a 45.8% three-year survival rate. WHO accepted proprietary brand name Herlystic for the therapy. Company plans early market access submissions in Q4 2026 across four regions.
1mo agoOS Therapies appoints Frank Knuettel II as CFO and Kerry Clem as CCO
OS Therapies appointed Frank Knuettel II as Chief Financial Officer. Kerry Clem was named Chief Commercial Officer. The company focuses on gene-edited, Listeria-based cancer immunotherapies.
1mo agoOS Therapies aligns with FDA on Phase 3 design, joins Project Orbis
OS Therapies aligns with FDA on adaptive Phase 3 trial design for OST-HER2. Company joins Project Orbis via MHRA leadership for global regulatory coordination. Patient previously lost to follow-up confirmed to be alive. CMAA submission expected in coming weeks; Phase 3 trial starts mid-Q4 2026. Received $3.15 million in VAT refunds with eligibility for additional $7.2 million.
1mo agoOS Therapies targets Q4 2026 BLA submission for OST-HER2
OS Therapies targets Q4 2026 for BLA submission and CMAAs for OST-HER2. FDA and MHRA statistical meetings scheduled for September 2026. Potential Priority Review Voucher could yield up to $220 million. OS Animal Health seeks USDA meeting in Q4 2026 for canine approval.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in OS Therapies is now worth
$ 29.88
Resulting in a loss of
$ 70.12 (70.12%)
Note: Past profits do not guarantee future returns.
